Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from BML ( (JP:4694) ).
BML, Inc. has announced a series of senior management and organizational changes approved by its Board of Directors on March 30, 2026, reflecting a strategic emphasis on genome-related services and systems operations. Representative Director and Vice-President Nobuki Arai will now oversee the Genome Medical Business Division and Genome QA Office, while maintaining responsibility for the BML Testing Division and the BML General Laboratory.
Director and Managing Executive Officer Kenji Shibata retains leadership of the BML Testing Division but relinquishes oversight of the Fourth General Laboratory Testing Department, signaling a redistribution of testing operations. In parallel, executive responsibilities around the Electronic Medical Record System Department and multiple system and genome business departments have been reassigned, aiming to strengthen BML’s capabilities in advanced genome services and medical IT infrastructure ahead of the April 1, 2026 effective date.
The most recent analyst rating on (JP:4694) stock is a Hold with a Yen4430.00 price target. To see the full list of analyst forecasts on BML stock, see the JP:4694 Stock Forecast page.
More about BML
BML, Inc., listed on the Tokyo Prime market under securities code 4694, operates in the medical testing and healthcare services sector. The company focuses on clinical laboratory testing, advanced genome and medical analysis businesses, and medical information systems, positioning itself as a key diagnostics and health IT provider in Japan.
YTD Price Performance: 7.77%
Average Trading Volume: 74,560
Technical Sentiment Signal: Buy
Current Market Cap: Yen155.6B
For detailed information about 4694 stock, go to TipRanks’ Stock Analysis page.